COX-2 Class Labeling From Vioxx/Celebrex Data Proposed By FDA Consultant

Class labeling for COX-2 inhibitors incorporating data from Pharmacia's Celebrex and Merck's Vioxx large-scale safety studies may be useful in explaining differential safety results in gastrointestinal and cardiovascular adverse events, a consultant to FDA's Arthritis Advisory Committee suggested Feb. 8.